Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease	Recruiting	Phase 2	2026-03-17		NCT06918431

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
City of Hope Medical Center	347
National Cancer Institute (NCI)	3015

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope at Irvine Lennar	Irvine	United States	104
City of Hope at Phoenix	Phoenix	United States	1
City of Hope Medical Center	Duarte	United States	313
Cleveland Clinic Foundation	Cleveland	United States	370
Memorial Sloan Kettering Cancer Center	New York	United States	1000
UC San Diego Moores Cancer Center	La Jolla	United States	199
UCLA / Jonsson Comprehensive Cancer Center	Los Angeles	United States	126
University of Chicago Comprehensive Cancer Center	Chicago	United States	273